Genomic Answers for Children’s Health Act of 2026

On January 15, 2026, Rep. Scott Peters (D-CA) introduced H.R. 7118, the Genomic Answers for Children's Health Act of 2026, in the 119th Congress. The bill has 17 cosponsors and has been referred to the House Committee on Energy and Commerce — its current status is early-stage. The bill amends Title XIX of the Social Security Act to explicitly cover whole genome sequencing (WGS) and whole exome sequencing (WES) as a first-tier test under Medicaid for children suspected of having a genetic disorder, rare disease, or condition of unknown origin, including congenital anomalies, global developmental delay, or intellectual disability. Importantly, the bill does not authorize or appropriate any specific dollar amount — it creates a coverage mandate, meaning the funding flows through existing Medicaid reimbursement mechanisms. Actual spending would depend on utilization rates and state-level implementation, but the structural effect is a guaranteed new revenue stream for sequencing companies. The money trail here is distinct from an appropriations bill. This is a coverage mandate: it does not allocate a lump sum, but rather requires state Medicaid programs to reimburse for WGS/WES when ordered by a physician. The Congressional Budget Office would score the cost as increased Medicaid outlays, but no separate authorization ceiling exists. The economic mechanism is demand expansion — by adding millions of pediatric Medicaid beneficiaries to the eligible patient pool, the bill increases the total addressable market for clinical sequencing. Illumina ($ILMN) is the primary beneficiary as the dominant platform provider for clinical WGS/WES, with its NovaSeq 6000 and NextSeq systems widely deployed in diagnostic labs. Thermo Fisher ($TMO) benefits through its Ion Torrent platform and clinical diagnostics portfolio, though the sequencing segment is a smaller share of TMO's overall $45B+ revenue. Pacific Biosciences ($PACB), with its long-read HiFi technology, is a smaller but higher-beta beneficiary if the mandate drives adoption for complex cases requiring structural variant detection. Real market data shows ILMN closing at $120.37 on April 29, 2026, down 4.04% over the past week and essentially flat over 30 days (-0.36%). The stock is trading well below its 52-week high of $155.53. PACB closed at $1.47, down 6.37% in the last week but up 16.67% over 30 days — suggesting some recent interest. TMO closed at $466.26, down 0.09% weekly and 2.87% monthly. The recent price action does not appear to reflect any anticipation of this bill, which is consistent with its early legislative stage. The market may be waiting for committee action or a hearing date before pricing in the probability of passage. The 7-day selloff in ILMN and PACB may represent broader market weakness rather than sector-specific news. The legislative timeline is uncertain. The bill has taken no action since referral to the House Energy and Commerce Committee on January 15, 2026. Passage requires committee markup, House floor vote, Senate companion legislation (none has been introduced as of this data), Senate committee and floor vote, and presidential signature. With 17 bipartisan cosponsors (including Reps. Bilirakis, Balderson, and Carey on the Republican side), there is notable cross-aisle support, but the early-stage status means this is a 2027-or-later event at best. Investors should monitor for a committee hearing as the next catalyst.